Health AI Startup OpenEvidence Reaches $15B Valuation

Miami-based health artificial intelligence startup OpenEvidence has closed a $250 million funding round that values the company at $15 billion, according to sources familiar with the matter. The investment, led by hospital systems and Andreessen Horowitz, marks a rapid acceleration for the firm, which priced a previous round at $12 billion in January. In just over twelve months, OpenEvidence has secured more than $1 billion from a roster of prominent investors, including Thrive Capital, DST, GV, Kleiner Perkins, Sequoia Capital, and Nvidia. Founded in 2022 by Dr. Daniel Nadler, OpenEvidence has quickly established its proprietary AI search engine as a critical clinical tool. The platform delivers diagnostic and treatment recommendations grounded in peer-reviewed medical literature, and has been adopted by more than two-thirds of physicians across the United States. Executives have characterized the product as the fastest-growing application in medical history, driven by its seamless integration into established clinical workflows and its adherence to strict data privacy standards. As the funding round closes, strategic considerations surrounding infrastructure and market positioning are taking center stage. Reports indicate OpenEvidence is evaluating potential acquisition interest, primarily motivated by access to computational resources. Growing regulatory and public scrutiny surrounding artificial intelligence has introduced potential bottlenecks in data center expansion, making high-performance compute a strategic constraint for independent scaling. While an acquisition could offer immediate access to the infrastructure required to handle increased workloads, sources suggest the company remains firmly inclined to maintain operational independence if viable terms can be secured. The financing arrives as major artificial intelligence incumbents, including OpenAI and Anthropic, transition from providing foundational models to deploying direct healthcare applications. OpenEvidence’s existing clinical user base, proven data handling protocols, and entrenched position within a highly regulated market present an immediate entry point for technology conglomerates seeking to capture the healthcare AI sector. Anthropic announced a strategic partnership with the startup earlier this week, and the platform already maintains compatibility with generative tooling from Google and Microsoft. The broader artificial intelligence sector is currently experiencing a wave of consolidation, underscored by recent high-value transactions such as Nvidia’s acquisition of Hugging Face and Stripe’s purchase of OpenRouter. OpenEvidence’s valuation surge and strategic positioning reflect intense competition among capital allocators to secure specialized AI infrastructure and domain expertise. With a validated clinical workflow and a rapidly expanding investor base, the company is positioned to influence how artificial intelligence is deployed at the point of medical care, regardless of whether it pursues independent scaling or integration with larger technology entities.